I have a broad background in molecular biology, with specific training and expertise in pharmacogenomics and drug repositioning in the field of cystic fibrosis. My research includes functional genomics analyses in cystic fibrosis (CF) in patient-derived bronchial cell and tissue cultures. I laid the groundwork for my postdoc research by developing effective meta-analysis strategies to repurpose cancer drugs for CF and by establishing a robust procedure to set up CFTR functional studies in primary cells obtained from CF patients’ explanted lungs. We generated and used the cell electrophysiology data to generate a selected compendium of drug-induced profiles. By characterizing the functional responses to CFTR modulators from different donors with the same CFTR genotype, I had noticed an individual contribution to the therapeutic efficacy of CFTR modulators.
Subsequently, an increasing number of scientific studies highlighted the importance of personalized medicine approaches in CF by revealing the unique features of each patient’s disease state, and therapeutic efficacy at the individual level. In order to pursue this novel precision medicine approach, I have been trained in clinical research, and I am responsible for pre-clinical research at the CF unit of Bambino Gesù Children’s Hospital of Rome, Italy. Together with CF physicians, we are working to redefine the patient needs, and to select translational approaches that are most likely to benefit CF patients.
I have a broad background in molecular biology, with specific training and expertise in pharmacogenomics and drug repositioning in the field of cystic fibrosis. My research includes functional genomics analyses in cystic fibrosis (CF) in patient-derived bronchial cell and tissue cultures. I laid the groundwork for my postdoc research by developing effective meta-analysis strategies to repurpose cancer drugs for CF and by establishing a robust procedure to set up CFTR functional studies in primary cells obtained from CF patients’ explanted lungs. We generated and used the cell electrophysiology data to generate a selected compendium of drug-induced profiles. By characterizing the functional responses to CFTR modulators from different donors with the same CFTR genotype, I had noticed an individual contribution to the therapeutic efficacy of CFTR modulators.
Subsequently, an increasing number of scientific studies highlighted the importance of personalized medicine approaches in CF by revealing the unique features of each patient’s disease state, and therapeutic efficacy at the individual level. In order to pursue this novel precision medicine approach, I have been trained in clinical research, and I am responsible for pre-clinical research at the CF unit of Bambino Gesù Children’s Hospital of Rome, Italy. Together with CF physicians, we are working to redefine the patient needs, and to select translational approaches that are most likely to benefit CF patients.